Ratifi English Iniciar sesión
Ratifi

Proyectos federales de Congress.gov. Proyectos estatales de Open States.

SF 1998Sesión 2025-2026

Dementia treatment medical services and prescription medications coverage requirement provision and step therapy requirements for medical assistance provision

Introduction 26 de febrero de 2025

El texto subrayado se agregaría a la ley vigente. El texto tachado se eliminaría.

Skip to main content Skip to footer Minnesota Legislature Advanced Search Search Legislature Search Menu
  • House
  • Minnesota House of Representatives House Members and Staff House Members Leadership Staff Employment Who Represents Me? Committees Committee List Committee Roster Upcoming Meetings Standing Committee Schedule Minutes Committee Deadlines Offices Chief Clerk Fiscal Analysis House Research Public Information Sergeant-at-Arms Caucuses - DFL/GOP Other Information House Journal House Rules Joint Rules Educational Programs Pronunciation Guide Address Spreadsheet
  • Senate
  • Minnesota Senate Senators and Staff Senators Leadership Staff Employment Who Represents Me? Committees Committee List Committee Roster Upcoming Meetings Standing Committee Schedule Committee Deadlines Offices Secretary of the Senate Senate Counsel, Research & Fiscal Analysis Caucuses - DFL/GOP Other Information Senate Journal Senate Rules Joint Rules Educational Programs Address Labels Subscriptions
  • Joint
  • Joint Department, Offices, and Commissions Joint Legislative Offices Legislative Budget Office Legislative Coordinating Commission (LCC) Legislative Reference Library Office of the Legislative Auditor Office of the Revisor of Statutes Commissions Legislative-Citizen Commission on MN Resources Legislative Commission on Pensions & Retirement Lessard-Sams Outdoor Heritage Council More... More Information Joint Offices Directory Joint Offices Staff Accessibility Legacy Amendment
  • Schedules
  • Schedules, Calendars, and Legislative Business House House Schedules Order of Business Calendar for the Day Supplemental Calendar for the Day Fiscal Calendar Senate Senate Schedules Order of Business Senate Calendar General Orders of the Day Joint Combined Upcoming Meetings Broadcast TV Schedule Committee Deadlines
  • Committees
  • Legislative Committees House Committee List Committee Roster Upcoming Meetings Standing Committee Schedule Minutes Senate Committee List Committee Roster Upcoming Meetings Standing Committee Schedule Joint Joint Committees & Task Forces Committee Deadlines Bills In Conference Committee Side by Side Comparisons
  • Bills
  • Bills House Bill Search & Status (House) Bill Introductions Bill Summaries Act Summaries Fiscal Tracking Sheets Senate Bill Search & Status (Senate) Bill Introductions Bill Summaries Act Summaries Fiscal Tracking Sheets Joint Bill Search & Status MyBills Side by Side Comparisons Bills In Conference Committee Vetoes Current Session Laws
  • Law
  • Statutes, Laws, and Rules Statutes Keyword Search Current Statutes Statutes by Topic (Index) Statutes Archive Session Laws Keyword Search Current Session Laws Session Laws by Topic (Index) Session Laws Archive Session Laws Changed (Table 1) Statutes Changed (Table 2) Administrative Rules Keyword Search Current Rules Rules by Topic (Index) Rules Archive Minnesota Rule Status State Register Other Legal Materials Minnesota Constitution State Constitutional Amendments Court Rules
  • Multimedia
  • Multimedia - Audio, Video, Broadcast TV, News, & Photos House Live Video Audio Webcast Schedule Audio & Video Archives Session Daily Photos Senate Live Video Audio Webcast Schedule Audio & Video Archives Senate Media Services Photos Joint Combined Media Page Legislative Media Archive Broadcast TV Schedule Commission Audio/Video
  • Publications
  • Legislative Research, Reports & Information Office Research & Reports House Fiscal Analysis House Research Senate Counsel Publications Legislative Auditor Revisor Publications Legislative Reference Library News House Session Daily Senate Media Services Senate Information Legislators Roster Member Guide Legislative History Legislative History Guide Legislators Past & Present House Journal Senate Journal Legislative Time Capsule Vetoes Notable Documents Fiscal Review Minnesota Issues Guides New Laws Books & reports
Search Legislature Search Office of the Revisor of Statutes

Office of the Revisor of Statutes

Revisor Menu
  • Retrieve by number Document type Statutes Laws Rules Bills GO
  • Statutes
  • Laws
  • Rules
  • Court Rules
  • Constitution
  • Revisor's Office Revisor Intranet Attorney Drafting Areas Staff Directory Office Duties Publications Educational Seminars Employment Openings Order Publications
  • Search Law by Keyword
  • Bills
  • 94th Legislature (2025 - 2026)
  • SF1998
  • Introduction

SF 1998

Introduction - 94th Legislature (2025 - 2026)

Posted on 02/24/2026 09:16 a.m.

KEY: stricken = removed, old language. underscored = added, new language. Version List SF1998 Authors and Status PDF Rtf

Bill Text Versions

Engrossments
Introduction PDF Posted on 02/26/2025
Jump to page/line # Line numbers 1.1 1.2 1.3 1.4 1.5 1.6
1.7 1.8 1.9 1.10 1.11 1.12 1.13 1.14
1.15 1.16
1.17 1.18 1.19 1.20 1.21 1.22 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 2.10 2.11 2.12 2.13 2.14 2.15 2.16 2.17 2.18 2.19 2.20 2.21 2.22 2.23 2.24 2.25 2.26 2.27 2.28 2.29 2.30 2.31 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 3.10 3.11 3.12 3.13 3.14 3.15 3.16 3.17 3.18 3.19 3.20 3.21 3.22 3.23 3.24 3.25 3.26 3.27 3.28 3.29 3.30 3.31
3.32

A bill for an act
relating to health insurance; requiring coverage of medical services and prescription
medications for the treatment of dementia; modifying step therapy requirements
for medical assistance; amending Minnesota Statutes 2024, section 256B.0625,
subdivision 13f; proposing coding for new law in Minnesota Statutes, chapter 62Q.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

Section 1.

new text begin [62Q.546] COVERAGE FOR DEMENTIA.
new text end

new text begin (a) A health plan company must provide coverage for every (1) type of medical service,
and (2) prescription medication approved by the United States Food and Drug Administration
that is used to treat or slow the progression of dementia. A health plan company must provide
coverage for diagnostic testing to determine the appropriateness or effectiveness of a medical
service or prescription medication to treat or slow the progression of dementia.
new text end

new text begin (b) A health plan company is prohibited from using step therapy protocol, as defined in
section 62Q.184, subdivision 1, when providing the coverage required under paragraph (a).
new text end

new text begin EFFECTIVE DATE. new text end

new text begin This section is effective January 1, 2026, and applies to health
plans offered, issued, or renewed on or after that date.
new text end

Sec. 2.

Minnesota Statutes 2024, section 256B.0625, subdivision 13f, is amended to read:


Subd. 13f.

Prior authorization.

(a) The Formulary Committee shall review and
recommend drugs which require prior authorization. The Formulary Committee shall
establish general criteria to be used for the prior authorization of brand-name drugs for
which generically equivalent drugs are available, but the committee is not required to review
each brand-name drug for which a generically equivalent drug is available.

(b) Prior authorization may be required by the commissioner before certain formulary
drugs are eligible for payment. The Formulary Committee may recommend drugs for prior
authorization directly to the commissioner. The commissioner may also request that the
Formulary Committee review a drug for prior authorization. Before the commissioner may
require prior authorization for a drug:

(1) the commissioner must provide information to the Formulary Committee on the
impact that placing the drug on prior authorization may have on the quality of patient care
and on program costs, information regarding whether the drug is subject to clinical abuse
or misuse, and relevant data from the state Medicaid program if such data is available;

(2) the Formulary Committee must review the drug, taking into account medical and
clinical data and the information provided by the commissioner; and

(3) the Formulary Committee must hold a public forum and receive public comment for
an additional 15 days.

The commissioner must provide a 15-day notice period before implementing the prior
authorization.

(c) Except as provided in subdivision 13j, prior authorization shall not be required or
utilized for any atypical antipsychotic drug prescribed for the treatment of mental illness
if:

(1) there is no generically equivalent drug available; and

(2) the drug was initially prescribed for the recipient prior to July 1, 2003; or

(3) the drug is part of the recipient's current course of treatment.

This paragraph applies to any multistate preferred drug list or supplemental drug rebate
program established or administered by the commissioner. Prior authorization shall
automatically be granted for 60 days for brand name drugs prescribed for treatment of mental
illness within 60 days of when a generically equivalent drug becomes available, provided
that the brand name drug was part of the recipient's course of treatment at the time the
generically equivalent drug became available.

(d) Prior authorization must not be required for liquid methadone if only one version of
liquid methadone is available. If more than one version of liquid methadone is available,
the commissioner shall ensure that at least one version of liquid methadone is available
without prior authorization.

(e) Prior authorization may be required for an oral liquid form of a drug, except as
described in paragraph (d). A prior authorization request under this paragraph must be
automatically approved within 24 hours if the drug is being prescribed for a Food and Drug
Administration-approved condition for a patient who utilizes an enteral tube for feedings
or medication administration, even if the patient has current or prior claims for pills for that
condition. If more than one version of the oral liquid form of a drug is available, the
commissioner may select the version that is able to be approved for a Food and Drug
Administration-approved condition for a patient who utilizes an enteral tube for feedings
or medication administration. This paragraph applies to any multistate preferred drug list
or supplemental drug rebate program established or administered by the commissioner. The
commissioner shall design and implement a streamlined prior authorization form for patients
who utilize an enteral tube for feedings or medication administration and are prescribed an
oral liquid form of a drug. The commissioner may require prior authorization for brand
name drugs whenever a generically equivalent product is available, even if the prescriber
specifically indicates "dispense as written-brand necessary" on the prescription as required
by section 151.21, subdivision 2.

(f) Notwithstanding this subdivision, the commissioner may automatically require prior
authorization, for a period not to exceed 180 days, for any drug that is approved by the
United States Food and Drug Administration on or after July 1, 2005. The 180-day period
begins no later than the first day that a drug is available for shipment to pharmacies within
the state. The Formulary Committee shall recommend to the commissioner general criteria
to be used for the prior authorization of the drugs, but the committee is not required to
review each individual drug. In order to continue prior authorizations for a drug after the
180-day period has expired, the commissioner must follow the provisions of this subdivision.

(g) Prior authorization under this subdivision shall comply with section 62Q.184.

(h) Any step therapy protocol requirements established by the commissioner must comply
with deleted text begin sectiondeleted text end new text begin sectionsnew text end 62Q.1841new text begin and 62Q.546. The commissioner must apply the step therapy
requirements of sections 62Q.1841 and 62Q.546 to service delivery under fee-for-service
new text end .

(i) Notwithstanding any law to the contrary, prior authorization or step therapy shall not
be required or utilized for any class of drugs that is approved by the United States Food and
Drug Administration for the treatment or prevention of HIV and AIDS.

new text begin EFFECTIVE DATE. new text end

new text begin This section is effective January 1, 2026.
new text end

About the Legislature
  • Historical Information
  • Employment/Internships
  • Visiting the Capitol
  • Accessibility
  • Frequently Asked Questions
Contact Your Legislator
  • Who Represents Me?
  • House Members
  • Senators
General Contact
  • Contact a legislative librarian:
  • (651) 296-8338 or Email
  • Phone Numbers
  • Submit website comments
Get Connected
  • House News
  • Senate News
  • MyBills
  • Email Updates & RSS Feeds
Minnesota Office of the Revisor of Statutes, Centennial Office Building, 3rd Floor, 658 Cedar Street, St. Paul, MN 55155

Texto oficial de la Legislatura de Minnesota. El formato se adaptó para leerlo en Ratifi.